Filter by: patients
Home > Community Treatment Reports and Side Effects > ALS Phase 1 Study NP001 Treatment Report
What is ALS Phase 1 Study NP001?

NCT01091142 is a completed single-ascending-dose safety and tolerability study of NP001 in subjects with Amyotrophic Lateral Sclerosis (ALS). Other study name is NP001 Single Dose - ALS.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Research 1 0
ALS (Amyotrophic Lateral Sclerosis) 1 0

See 1 patient currently using ALS Phase 1 Study NP001

Mouse over the table for more information

Reported Schedules

  3 other monthly 5 other monthly
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 1 Study NP001 (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped using ALS Phase 1 Study NP001

Reported Duration See details about how long patients take this treatment ▼

Currently Using ALS Phase 1 Study NP001

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Report created on May 28, 2012.